In GBS patients, parts of the body suddenly become numb, muscle weakness develops, and they may also face difficulty in ...

After GBS outbreak in Madhya Pradesh’s Neemuch district, doctors explain how the immunological disorder presents in children, ...

LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a ...

Annexon, Inc. (ANNX) was able to achieve positive results from its phase 3 study for the treatment of patients with Guillain-Barré syndrome [GBS]. Matter of fact, it noted that a lower dose of its ...

At least two people died after a Guillain-Barré Syndrome outbreak in Madhya Pradesh's Neemuch district. So far 14 patients ...

Real-world evidence study shows ANX005 improves muscle strength and functional outcomes in Guillain-Barré Syndrome compared to current treatments. Potential regulatory concerns may arise if the FDA ...

GBS is a disease in which a patient’s immune system mistakenly starts attacking the peripheral nervous system. The disease is ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long-term ...

State government includes costly GBS therapy in Ayushman Bharat–Arogya Karnataka scheme, offering financial support to affected patients.

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...

BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...

Two deaths and 14 cases of Guillain-Barré Syndrome reported in Neemuch, Madhya Pradesh. State ramps up detection, treatment, ...